Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

994 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer.
Dunphy MPS, Pressl C, Pillarsetty N, Grkovski M, Modi S, Jhaveri K, Norton L, Beattie BJ, Zanzonico PB, Zatorska D, Taldone T, Ochiana SO, Uddin MM, Burnazi EM, Lyashchenko SK, Hudis CA, Bromberg J, Schöder HM, Fox JJ, Zhang H, Chiosis G, Lewis JS, Larson SM. Dunphy MPS, et al. Among authors: norton l. Clin Cancer Res. 2020 Oct 1;26(19):5178-5187. doi: 10.1158/1078-0432.CCR-19-3704. Epub 2020 May 4. Clin Cancer Res. 2020. PMID: 32366671 Free PMC article. Clinical Trial.
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K. Kauff ND, et al. Among authors: norton l. N Engl J Med. 2002 May 23;346(21):1609-15. doi: 10.1056/NEJMoa020119. Epub 2002 May 20. N Engl J Med. 2002. PMID: 12023992 Free article.
Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer.
Modi S, Panageas KS, Duck ET, Bach A, Weinstock N, Dougherty J, Cramer L, Hudis C, Norton L, Seidman A. Modi S, et al. Among authors: norton l. J Clin Oncol. 2002 Sep 1;20(17):3665-73. doi: 10.1200/JCO.2002.08.057. J Clin Oncol. 2002. PMID: 12202668 Clinical Trial.
Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.
Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, Michaelson RA, Kirshner JA, Fleming GF, Perry MC, Graham ML, Sharp SA, Keresztes R, Henderson IC, Hudis C, Muss H, Norton L. Winer EP, et al. Among authors: norton l. J Clin Oncol. 2004 Jun 1;22(11):2061-8. doi: 10.1200/JCO.2004.08.048. J Clin Oncol. 2004. PMID: 15169793 Clinical Trial.
Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments.
Dang CT, Dannenberg AJ, Subbaramaiah K, Dickler MN, Moasser MM, Seidman AD, D'Andrea GM, Theodoulou M, Panageas KS, Norton L, Hudis CA. Dang CT, et al. Among authors: norton l. Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4062-7. doi: 10.1158/1078-0432.CCR-03-0463. Clin Cancer Res. 2004. PMID: 15217939 Clinical Trial.
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer.
Dang CT, D'Andrea GM, Moynahan ME, Dickler MN, Seidman AD, Fornier M, Robson ME, Theodoulou M, Lake D, Currie VE, Hurria A, Panageas KS, Norton L, Hudis CA. Dang CT, et al. Among authors: norton l. Clin Cancer Res. 2004 Sep 1;10(17):5754-61. doi: 10.1158/1078-0432.CCR-04-0634. Clin Cancer Res. 2004. PMID: 15355903 Clinical Trial.
994 results